Although the types of cancer reported in the literature (including bladder cancer, triple negative breast cancer, endometrial stromal sarcoma, lung cancer), types of ICIs (anti-PD1, anti-PD-L1 and even anti-CTLA-4), and treatment (first-line or non first-line ICIs treatment) were different, it was confirmed that patients with MDM2/MDM4 amplification had no positive reaction to ICIs [102–104]. The gene discussed is MDM2; the disease is lung cancer.